Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c

Sutro Biopharma Inc. (NASDAQ: STRO) reported Q2 EPS of ($2.33), $0.13 worse than the analyst estimate of ($2.20). Revenue for the quarter came in at $9.84 million versus the consensus estimate of $11.58 million.

For earnings history and earnings-related data on Sutro Biopharma Inc. (STRO) click here.

You May Also Be Interested In

• KeyBanc Starts PPG Industries (PPG) at Overweight
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Mizuho Starts Chesapeake Utilities (CPK) at Outperform